1. Scrip
  2. >>Business
  3. >>Deals

Provention Builds On J&J Disease Interception Model

 
• By Joseph Haas

Founded earlier in 2017 with a plan of making quick "go/no-go" development decisions based on objective data, Provention taps into Johnson & Johnson for a pair of IBD candidates.

businessman and businesswoman are shaking hands and exchanging folder after agreement was reached

Founded earlier this year to develop other firms’ candidates to intercept or prevent immune-mediated diseases, Provention Bio Inc. added its first two clinical candidates – both targeted at inflammatory bowel disease – by licensing a pair of candidates Sept. 21 from Janssen Pharmaceutica NV.

Not coincidentally, Janssen parent Johnson & Johnson is focused on moving beyond traditional treatment of diseases, having launched a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Deal Watch: XOMA Buys Troubled Alkermes-Spinout Mural Oncology

 
• By Joseph Haas, Xu Hu, and Lisa Takagi

Plus deals involving Fosun/Accro, Fosun/Sitala, RemeGen/Santen, Firebird/Solasia and more, including tech transfer.

Novo Adds Another Prong To Its RNA Ambitions With Replicate Deal

 
• By Jessica Merrill

Replicate is a clinical-stage company developing a next-generation self-replicating RNA technology. CEO Nathanial Wang talked to Scrip about the deal.

Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals

 
• By Andrew McConaghie

Superluminal’s CEO Cony D’Cruz believes its focus on GPCRs has already yielded a best-in-class obesity candidate for its own pipeline, as well as its $1bn- plus deal with Eli Lilly.

MannKind Snaps Up scPharmaceuticals In Cardiorenal Expansion

 
• By Sushmita Panda

The deal, which could be worth as much as $360m, marks the Danbury, CT-based firm's strategic expansion into cardiorenal medicine.

More from Business

Norway’s Nykode Upbeat About Cancer Vaccines After Tough Year

 
• By Kevin Grogan

The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.

MannKind Snaps Up scPharmaceuticals In Cardiorenal Expansion

 
• By Sushmita Panda

The deal, which could be worth as much as $360m, marks the Danbury, CT-based firm's strategic expansion into cardiorenal medicine.

Nippon Kayaku Aims To Broaden Portfolio Via Singaporean JV

 
• By Lisa Takagi

Mid-sized, diversified Japanese group teams up with Singaporean wholesaler Formiica and Japanese trading/contract services firm CBC for Singapore JV focused on in-licensing in Asia/Oceania.